Eli Lilly lifts sales view by $2 billion on soaring weight-loss drug demand

Eli Lilly (LLY.N) raised its annual revenue forecast by $2 billion on Tuesday due to strong demand and a steady ramp up of production of its weight-loss treatment Zepbound and related diabetes drug Mounjaro, lifting its shares about 7%.